Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9065835 | 0.96 | LMNA (0.54) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL15071452 | 0.91 | LMNA (0.49) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL14085637 | 0.90 | LMNA (0.48) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL9065826 | 0.89 | LMNA (0.50) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL14085638 | 0.87 | LMNA (0.46) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL14887276 | 0.85 | LMNA (0.44) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL25602128 | 0.84 | LMNA (0.44) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL14399514 | 0.83 | ALDH1A1 (0.56) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL24121572 | 0.83 | HPGD (0.45) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL16318074 | 0.82 | LMNA (0.52) | LMNAALDH1A1MAPK1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0130680-A2 | Cure to elastomers composition | LOCTITE CORPORATION (US) | 1985-01-09 | — | — | EP | claimed |
| US-4439600-A | Cure to elastomers compositions | LOCTITE CORPORATION (US) | 1984-03-27 | — | — | US | claimed |
| US-20090278084-A1 | Cure accelerators for anaerobic curable compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090278084-A1 | Cure accelerators for anaerobic curable compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-5096963-A | In a crystal matrix, storage stability, adhesives, coatings, sealants | LOCTITE CORPORATION (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0114117-B1 | RAPID CURE ACRYLIC MONOMER SYSTEMS | LOCTITE CORPORATION (US) | 1986-09-24 | — | — | EP | disclosed |
| US-4574138-A | FREE RADICAL CATALYST, URETHANE ACRYLATE | LOCTITE CORPORATION A CT CORP | 1986-03-04 | — | — | US | disclosed |
| EP-0130680-A2 | Cure to elastomers composition | LOCTITE CORPORATION (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0114117-A1 | Rapid cure acrylic monomer systems | LOCTITE CORPORATION (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4439600-A | Cure to elastomers compositions | LOCTITE CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090278084-A1 | Cure accelerators for anaerobic curable compositions | EGLN3, INO80, IDH2 | LMNA 1989/4885ALDH1A1 554/4885MAPK1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.